Hyderabad-based Dr Reddy’s Laboratories has acquired a portfolio of branded and generic injectable products from US-based Eton Pharmaceuticals.

The portfolio includes the Biorphen (phenylephrine hydrocholoride) Injection and Rezipres (ephedrine hydrochloride) Injection NDAs with nine separate combinations of strengths and presentations and one first-to-file approved ANDA for Cysteine Hydrochloride for the US. One strength each of Biorphen and Rezipres are currently commercially available in the US. The acquisition will complement Dr Reddy’s US institutional business with limited competition in injectable products.

Under the terms of the agreement, Dr Reddy’s acquired the Eton portfolio for an upfront payment of approximately $5 million in cash, plus contingent payments of up to $45 million. The acquisition supports Dr Reddy’s efforts to accelerate and expand affordable medications for patients.